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The antibody response is dependent upon interleukins that induce activation,
proliferation, and terminal differentiation ofB cells . The latter events, namely the
production ofplasma cells secreting Ig in high amounts are mainly induced by the
cytokine B cell stimulatory factor 2 (BSF2) t , now termed IL-6 (1) . The interleukins,
including IL-6, are all pleiotropic, and rDNA cloning has now shown that previ-
ously cloned IFN-(32 (2), 26-kD inducible protein (3), and hybridoma/plasmacy-
toma growth factor (4) are identical to BSF2 or IL-6 (5, 6) . Although IFN-(32 was
originally derived from human fibroblast lines induced with stimuli that result in
production ofIFN-a, several studieshave now shown that IL-6 does not have IFN-/3
activity (7, 8) . Other effects of IL-6 include stimulation of hematopoietic stem cells
(9), nerve cells (10), and hepatocytes to produce acute-phase proteins (11) . IL-6 is
also produced byT cells and monocytes/macrophages, andinducesthymocyte growth
and differentiation ofmatureT cells (12-14). Thereceptor forIL-6 (IL-6R) has now
been characterized (15) and cloned (16), and the IL-6R is present on activated B
cells, e.g ., multiple myelomas and EBVtransformed B cell lines (1, 17) .
Models have been proposed to explain interleukin-sensitive stages in Bcell differen-
tiation . Forexample, the sequential steps ofB cell activation, division, andterminal
differentiation are mainly influenced by IL-4, IL-5, and IL-6, respectively (1) . In
this regard, small, resting B cells express IL-4R, and IL-4 promotes entry into cell
cycle with an associated increase in class IIMHC antigen expression (18, 19) . LPS-
induced B cell blasts have been shown to express receptors for IL-5 (20), which are
absent on noncycling cells, clearly suggesting that B cell blasts arethe IL-5-responsive
subset . Receptors for IL-6 have been demonstrated only on activated and dividing
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B cells and on B cell and plasma cell tumor populations (15, 16). It has also been
shown that cytokines regulate movement of B cells through restriction points in the
cell cycle (21). One of these occurs in G, where macrophage-derived factors are es-
sential, while a second occurs 2-4 h before division (Gz) and is controlled by IL-2
and IL-5, but not by IL-3 or IL-4 (22).
Our own studies have been directed toward determining the principal cytokines
involved in the mucosal IgA response. Antibody ofthe IgA isotype comprises 60-65 0 /0
of the total Ig produced dailyin higher mammals (23) . IgA associated with mucosal
surfaces is produced locally by IgA plasma cellsdistributed in the subepithelial spaces
of mucosal membranes and in secretory glands, such as the lacrymal and salivary
glands (24). Peyer's patches (PP) are major IgA inductive sites and contain B cells
that are the precursors of IgA plasma cells at mucosal effector sites (25, 26). The
PP contain both small, resting and blast B cell populations, and B cells that have
recently committed to IgA (membrane IgA + [mIgA']) (26). In this study, we have
analyzed the effects of recombinant mouse and human IL-6 on various PP B cell
subsets to determine the role of this interleukin in regulation of IgA synthesis.
Materials and Methods
Murine IL-6.
￿
Murine rIL-6 (mrIL-6) was obtained as a reverse-phase HPLC-purified
protein derived from transfected COS-7 cell supernatants (27). Briefly, GY30 bone marrow
stromal cells were induced for 7 h with human rIL-1 at -650 U/ml. Total cellular RNA was
extracted using the guanidinium isothiocyanate method (28) and poly(A)' RNA was selected
by oligo(dT)-cellulose chromatography. cDNA libraries were constructed by the method of
Okayama and Berg (29) using the pcD-SRa plasmid vector (30). pcD-mIL-6 plasmid DNA
was transfected into COS-7 monkeys cells and mrIL-6 was purified by reverse-phase HPLC.
mrIL-6 was >95% pure as shown by SDS-PAGE analysis (31). Units of mrIL-6 were deter-
mined using the factor-dependent cell line NFS-60. 10 U/ml IL-6 was defined as the concen-
tration of IL-6 inducing half-maximal stimulation of NSF60 cells as determined by the MTT
colorimetric assay (32).
Human IL-6 and Polyclonal Anti-IL-6 Antibody.
￿
Human rIL-6 (hrIL-6) was prepared by
expressing a cDNA for IL-6 in Escherichia coli followed by further purification, the details
of which are described elsewhere (6, 33) . Briefly, the plasmid pTBCDF12, which contains
the E. coli trp promoter for expression, was constructed in order to generate a pT9-11 fusion
protein. The translated fusion protein was then digested with kallikrein and aminopeptidase-
P to obtain biologically active hrIL-6. This recombinant material was further purified by
reverse-phase HPLC. The purity of hrIL-6 was >95%, as shown by SDS-PAGE analysis,
and 105 U/19.3 Ag/ml of hrIL-6 was used as the starting material in this study. To obtain
the polyclonal antibody to human IL-6, a goat was immunized with hrIL-6. This antiserum
neutralized 1 U/ml of hrIL-6 activity at a dilution of 10-5 ; however, this antibody did not
neutralize human IL-2, IL-4, or IL-5.
Source ofCytokines.
￿
mrIL-4 and IL-5 were obtained from HeLa cells transfected with cDNA
for IL-4 (34) and IL-5 (35). These interleukins were purified from concentrated culture su-
pernatants as previously described (36). mrIL-la was generously provided by Drs. A. Stern
and P. Lomedico (Hoffman-La Roche Inc., Nutley, NJ) . hrIL-2 and mrTNFcl were kind
gifts from Biogen Corp. (Cambridge, MA). mrIFN-y was kindly provided by Genentech (South
San Francisco, CA). Purified human platelet-derived transforming growth factor /3 (TGF)3)
was purchased from Collaborative Research Inc. (Bedford, MA). TGF0 was >95% pure,
as shown by SDS-PAGE analysis, giving a single band of 25 kD under nonreducing condi-
tions and a single band of 12.5 kD under reducing conditions. TGF-(3 supported the growth
of normal rat kidney cells cultured in soft agar with a half-maximal colony-forming response
occurring at 1.35 ng TGF)3 per milliliter of culture medium. mrIL-7 was kindly provided
by Immunex Corp. (Seattle, WA) (37).BEAGLEY ET AL.
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Cytokine Assays.
￿
Both hrIL-2 and mrIL-4 were assayed on the HT-2 factor-dependent cell
line (38), as previously reported (36). For assessment of mrIL-4 activity, appropriate dilu-
tions were tested in the presence (or absence) of the anti-IL-4 antibody derived from the
B cell hybridoma 111111, generously provided by Dr. W. Paul (National Institutes of Health,
Bethesda, MD) (39). The mrIL-1a activity was assessed in the C3H/Hej thymocyte comito-
genic assay (40). The activity of mrIL-5 was measured using the dextran-sulfate B cell co-
stimulation assay as previously reported (36). Finally, mrIFN-y was assessed by inhibition
ofgrowth ofWEHI 279, an IFN--y-sensitive cell line (41) kindly provided by Dr. K. Bottomly
(Yale University School of Medicine, New Haven, CT).
Mice. C3H/HeN mice obtained from the Frederick Cancer Research Facility (NCI,
Frederick, MD) were maintained in horizontal laminar flow cabinets and provided food and
water ad libitum. All mice used were between 7 and 12 wk old.
Preparation ofPP B Cells.
￿
PP were aseptically removed and dissociated usingthe enzyme
Dispase® (Boehringer Mannheim Biochemicals, Indianapolis, IN) inJoklik-modified medium
(Gibco Laboratories, Grand Island, NY) (42). Cells were cultured overnight at 2 x 106
cells/ml in a 75-mlflaskin complete medium consisting ofRPMI 1640 (Gibco Laboratories)
supplemented with 1 mM sodium pyruvate, 2 MM L-glutamine, nonessential and essential
amino acids, 5 x 10-5 M 2-ME, gentamycin, and 10% (vol/vol) FCS (Flow Laboratories,
Inc., McLean, VA). B cells were prepared by panning on petri plates (15 x 100 mm; Falcon
Labware, Oxnard, CA) coated with goat IgG anti-mouse F(aV)2 as previously described (43).
The adherent B cell population was then treated with a rat monoclonal anti-T cell cocktail
(antiThy-1.2, Clone HO-13-4 [44]; anti-Lyt-2, Clone 53.6-72 [44]; and anti-L3T4, Clone
GK1.5 [45] for 30 min at 4°C followed by incubation (30 min at 4°C) with monoclonal anti-rat
is chain [Clone MAR 18.5 [46]), then incubated for 30 min at 37'C with a 1/10 dilution of
baby rabbit complement (Pel-Freeze Biologicals, Rogers, AR). Cells obtained by this method
were >98% mIg'.
B Cell Fractionation.
￿
Purified PP B cells were fractionated on discontinuous Percoll gra-
dients as previously described (36, 43). Briefly, Percoll (Pharmacia Fine Chemicals, Piscataway,
NJ) was diluted 9/1 with 10x HBSS (Gibco Laboratories). From this 100% stock solution,
50, 60, 65, and 70% Percoll solutions were made by dilution in 1 x HBSS. Gradients were
prepared by layering 2-ml aliquots of 70, 65, 60, and 50% Percoll in a 15-ml centrifuge tube
(Falcon No. 2057; Becton Dickinson & Co., Palo Alto, CA). A suspension of 3-5 x 107
purified B cells in 1 ml ofincomplete medium (RPMI 1640 supplemented with Hepes buffer,
L-glutamine, sodium pyruvate, nonessential amino acids, gentamycin, penicillin, and strep-
tomycin) was carefully layered over the 50% Percoll layer and the gradient was centrifuged
at 2,000 rpm for 20 min at 4°C (with the brakeoff). Fractions were collected from the Percoll
interfaces with a Pasteur pipette and washed twice in incomplete medium before use in in
vitro assays.
Depletion/Enrichment ofmIgA' B Cells.
￿
For the depletion or enrichment of mIgA' B cells,
PP B cells were stained with FITC-conjugated goat anti-mouse a chain(Southern Biotech-
nology Associates [SBA], Birmingham, AL) for 30 min at 4°C. Cells were then washed twice
with incomplete medium and resuspended at 5 x 106 cells/ml for cell sorting. Cell separa-
tions were performed by use of the FACStar® (Becton Dickinson & Co., Mountain View,
CA) and FITC-anti-a-treated B cell populations were sorted into mIgA' and mIgA- cell
fractions. According to the flow cytometry profile, brightly stained cells (4-6%) were col-
lected as mIgA' B cells.
In Vitro Cultures.
￿
Purified unsorted PP B cells or mIgA-depleted PP B cells were cultured
in complete medium at 105 cells in 0.2 ml total volume/well in 96-well flat-bottomed micro-
titer plates (Falcon Labware), and rmIL-6 was added to give final concentrations of 0.5, 5,
50, and 150 U/ml. mIgA' B cells were cultured at 5 x 104 cells per well. All cultures were
incubated for 7 d at 37°C in a humidified atmosphere of 83% N2, 7% 02, and 10% C02.
Isotype-speck RIA.
￿
Solid-phase absorbed and affinity-purified goat IgG antibodies specific
for murine A, -y, and a H chains were obtained from SBA. Their specificity was confirmed
in RIA using purified mAbs and appropriate myeloma proteins as substrates. Radioiodina-
tion with carrier-free Na '2'1 (Amersham Corp., Arlington Heights, IL) was performed using
the chloramine T method, modified to reduce oxidative damage to proteins (47).2136
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Immulon Remova well assay strips (Dynatech Laboratories, Chantilly, VA) were coated
with goat anti-mouse IA, -y, or a at 1 wg/ml in borate-buffered saline, pH 8.4, overnight at
4°C. Control strips were left uncoated, but all strips were blocked for 2 h at 25°C with 1°Io
(wt/vol) BSA (Sigma Chemical Co.) in borate-buffered saline, which was also used as the
diluent for all samples and 1251-labeled reagents. Appropriate dilutions of tissue culture su-
pernatants were added to washed wells in triplicate and incubated for 6 h at 25°C. After
washing, 100,000 counts/min of 1251-labeled isotype-specific anti-Ig reagent was added to each
well and incubated overnight at 4°C. After removal of the unbound 1251 antibodies by
washing, the cells were counted in a gamma 5500 spectrometer (Beckman Instruments, Ir-
vine, CA). Calibrations were made using serial twofold dilutions of purified mAb 1F3-C1.5
or 2E11 .15 for IgM and IgA, respectively, or a standard mouse serum (Miles Laboratories,
Naperville, IL) for IgG. Calibration curves and interpolation of unknowns were obtained
by computer using a "Logit-log" BASIC program (RIA 001; Biomedical Computing Tech-
nology Center, Vanderbilt Medical Center, Nashville, TN).
Enumeration ofIgA-producing Cells.
￿
To quantitate the number of antibody-forming cells,
the enzyme-linked immunospot (ELISPOT) assay (48) was used. For this assay, 96-well nitrocel-
lulose bottom plates (Millititer HA; Millipore Corp., Bedford, MA) were coated overnight
at 4°C with goat anti-mouse Ig (SBA) diluted to 5 hg/ml in PBS (100141/well). Control wells
were coated with PBS. All wellswere then blocked for 60 min with complete medium. IL-6-stim-
ulated or control PP B cells (5 x 103 to 5 x 104 cells/well) were incubated on coated plates
in 100 pl of complete medium for 6-8 h. The plates were then thoroughly washed with PBS
containing 0.05% Tween (PBST) and then incubated with 100 p.l/well biotin-labeled goat
anti-mouse IgA (SBA) diluted 1 :1,000 in PBST containing 1° / FCS. After overnight incu-
bation at 4°C, the plates were washed three times with PBST then incubated for 2 h with
100 jut/well avidin-peroxidase diluted 1 :1,000 in PBS-T. Spots representing single antibody
producing cells were developed using 3-amino-9-ethylcarbazole as substrate, and visualized
with the aid of a dissecting microscope. The results are presented as the mean ± SD for
triplicate determinations.
Results
Cytokine-mediatedSupportofIgA Synthesis by PP B Cells.
￿
Although numerous studies
have examined the ability of various purified natural and recombinant cytokines
to regulate the level and isotype of Igs secreted by activated B cells, few experimental
systems have allowed an examination of defined leukocyte-derived factors that sup-
port commitment to, and secretion of, IgA antibodies(26). The levels ofIgA secreted
by cytokine-supported cultures of LPS-stimulated spleen B cellshave been uniformly
low, and the possible skewing of the isotype profile by LPS induction cannot be dis-
counted. Our previous studies have shown that high levels of IgA are secreted by
cultures ofnoninduced PP B cells supplemented with mrIL-5 (36). As an extension
of this work, we have used cultures of purified PP B cells to systematically examine
the ability of interleukins and cytokines to support the later stages of B cell differen-
tiation to the secretion of IgA. Extensive titrations of seven recombinant human
and mouse interleukins (mrIL-1a, hrIL-2, mrIL-4, mrIL-5, mrIL-6, hrIL-6, and
mrIL-7) and three additional cytokines (mrIFN-y, mrTNFa, and platelet-derived
TGF0) revealed that only mrIL-5 and rIL-6 (murine and human) significantly en-
hanced IgA secretion by PP B cells(Fig. 1). While none of the other factors increased
the level of IgA in the culture supernatants by >50%, the IL-5 and IL-6 prepara-
tions supported -400 and 1,000% of the IgA secreted in the control cultures, respec-
tively. Both the murine and human rIL-6 reproducibly induced secretion ofapprox-
imately twice the amount of IgA compared with IL-5, and therefore the activities
of this interleukin were investigated in greater detail.0
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FIGURE 1.
￿
Thepotentialeffects
ofcytokineson IgAsynthesis in
PP Bcell cultures. In this study,
the cytokines mrIL-la (100
U/ml), hrIL-2 (100 U/ml),
mrIL-4 (10 U/ml), mrIL-5 (50
U/ml), mrIL-6 (50 U/ml),
hrIL-6 (50 U/ml), mrIL-7 (50
U/ml), mrIFN--y (100 U/ml),
mrTNFa (2.5 ng/well) and
TGF/3 (40pg/ml) (see details in
Materials and Methods) were
addedto purified PP Bcell cul-
tures (105 B cells/well) and in-
cubated for 7 d. Each cytokine
was titrated in an appropriate
bioassay; in these studies mul-
tiple dosesofeach cytokine were
addedandtheresults presented
are typical responses in these
cultures. Levels of IgA in the
culture supernatant was deter-
mined by RIA. Values are the
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control cultures (eight experi-
ments) was 1,276 t 637 ng/ml.
mrIL-6 Selectively Enhances IgA Secretion by PP B Cells.
￿
The ability of mrIL-6 to
influence the relative proportions of IgM, IgG, and IgA secreted by PP B cells in
the absence of any other exogenous stimulus was tested across a range of concentra-
tions to examine whether this lymphokine plays a role in determining the enrich-
ment for IgA production characteristic of the cells from this mucosal tissue (Fig.
2). mrIL-6 exhibited a dose-dependent abilityto enhance IgA synthesis, with apeak
response 5-20 times that of control cultures. In contrast, IgM and IgG secretion
wasonly marginally increasedby this lymphokine, regardless of thedose used. Com-
parison of thelevels ofeach isotypeinducedby optimal doses of mrIL-6 and mrIL-5
revealed that mrIL-6 is not as effective as mrIL-5 at supporting IgM or IgG syn-
thesis, despite the fact that it supports a substantially higher level of IgA secretion.
These results illustrate that both of these interleukins preferentially support IgA secre-
tion by PP B cells, and that this effect is more pronounced, both in absolute amount
and relative to IgM and IgG, with mrIL-6.
mrIL-6 and hrIL-6 Induce IdenticalActivities in Mouse PP B Cells.
￿
hrIL-6 has re-
cently been shown to augment Ig secretion in PWM-stimulated human B cell cul-
tures, and to induce mouse hemopoietic colony formation (1, 9). Direct comparison
of the effects ofmrIL-6 andhrIL-6 aftertheir addition to cultures ofPP Bcellsdemon-
stratedthat they possessedessentially identical abilities to support Ig synthesis (Fig.
3). Both caused a dose-dependent increase in antibody secretion that was almost
exclusive for the IgA isotype. The availability of goat antiserum specific to human
IL-6 allowedacontrolexperiment to be performed to confirmthat theenhancement
of IgA synthesis by PP B cells is a property of IL-6. Inclusion of the anti-IL-6 an-
tiserum at afinal concentration of 1:200 in the IL-6 supplemented cultures resulted2138
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FIGURE 2 . mrIL-6 effects on Ig
synthesis in PP B cell cultures.
Purified PP B cells were cultured
at 105 cells/culture for 7 d in the
presence of increasing amounts of
mrIL-6 and mrIL-5 (50 U/ml) .
Levels of IgM (p), IgG(Q), and
IgA (/) in culture supernatants
were determined by isotype-specific
RIA . Values are representative of
the mean t SD of triplicate cul-
tures for five separate experiments .
FIGURE 3 .
￿
hrIL-6 effects on Ig
synthesis by PP B cells . PP B
cells obtained by panning were
cultured at 105 cells/well with
hrIL-6 andmrIL-6 for 7 d .IgM
(0), IgG ((]), and IgA (/)
levels in culture supernatants
were determined by isotype-
specific RIA . Values represent
the mean f SD of triplicate
cultures .in a 98% reduction in IL-6-mediated IgA secretion, while normal goat serum was
without effect (Fig. 4).
mrIL-6 Acts Predominantly on LowDensityPP B Cells.
￿
Human tonsillar B cellshave
been shownto be refractory to human IL-6 unless they arefirstactivated with mitogens
(1), and we have shown that the IL-5-responsive B cells in mouse PP are predomi-
nantly in the low density(activated) fraction (36). To determinethe activation status
of the cells responding to IL-6, PP B cells were cultured in the presence of various
concentrations of IL-6 after fractionation into low density (activated) and high den-
sity (predominantly resting) populations on discontinuousPercollgradients. Deter-
mination of the levels of IgM, IgG, and IgA in the culture supernatants after 7 d
ofculture indicated that the cells that responded to IL-6 with increased Ig synthesis
were enriched in the low density fraction (Fig. 5). As in the case of unfractionated
PP cells, the predominant isotype secreted by both the high and low density cells
was IgA. While the enhancement of Ig secretion by mrIL-6, as well as that previ-
ously demonstrated with mrIL-5 (36), is pronounced in the low density (activated)
cell fraction, theredoes not appear to be astrict correlation between membrane iso-
type expression by activated PP B cells and isotype secretion. Although a higher
proportion of the PP mIgA+ cells are in cycle compared with mIgA- cells, the ab-
solute number of cycling mlgM+, mIgA - cells is several times higher than that of
mIgA+ cells (36). Despite the enrichment ofthe activated mIgM+ cells into the low
density fraction, virtuallyno enhancementofIgM secretionis observed in the pres-
ence of IL-6. Thus, these results demonstrate that the PP B cells that respond to
IL-6 with increased Ig secretion are in cycle and that those PP B cells destined for
IgA secretionare uniquely sensitive to thedifferentiation-supporting activity ofthis
interleukin.
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FIGURE 4.
￿
Goat anti-human IL-6 inhibits hrIL-6-mediated IgA secretion. Purified PP B cells
were cultured for 7 d at 105cells/culture with hrIL-6 at 50 U/ml. Goat anti-human IL-6 (1 :200
final dilution) and normal goat serum (1 :200) were added to cultures 30 min before addition
of B cells. IgA levels in culture supernatants were determined by isotype-specific RIA. Values
represent the mean t SD of triplicate cultures.2140
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rmIL-6 Added
Large B Cells (Low Density)
￿
(U./ml)
￿
Small B Cells (High Density)
None
5
50
150
0.5
8,000 6,000 4,000 2,000 0
￿
0 2,000 4,000 6,000 8,000
Immunoglobulin Synthesis (ng/ml)
￿
Immunoglobulin Synthesis (ng/ml)
FIGURE 5.
￿
mrIL-6 effects on PP B cell subpopulations separated on Percoll density gradients.
Purified PP B cells obtained by panningwere separated into large B cells (50 and 60% Percoll
interfaces) and small Bcells(65 and 70% Percoll interfaces) and were cultured at 105cells/culture
for 7 dwith increasing amounts of mrIL-6. IgM (Eg), IgG(EI), andIgA (/) levels in culture
supernatants were determinedby isotype-specific RIA. Values represent themean t SD oftriplicate
cultures.
The PP B Cells that Respond to mrIL-6 with IncreasedIgA SynthesisAremIgA'.
￿
A cen-
tral issue pertaining to mucosal immune inductive sites, such as the PP, involves
the mechanism(s) through which they are predisposed to the selective induction of
IgAclassantibody responses. Todifferentiate betweenthepossibilities thatIL-6directs
isotype switching, as opposed to selectively potentiatingthe differentiation ofprevi-
ously committed B cells, flow cytometric sorting was used to separate PP B cells
into mIgA' and mIgA' subpopulations. Culture ofthese separate subpopulations
inthe presence ofvariousconcentrationsofIL-6, followed by analysis ofthe secreted
Igs for the levels ofIgM, IgG, and IgA, clearly demonstrated that the cells that se-
crete IgA in response to IL-6 express mIgA at the initiation ofthe culture (Fig. 6).
Removal of the mIgA' cells abolished both background and IL-6-supported IgA
secretion. In contrast, the enriched mIgA+ subpopulation responded in a dose-de-
pendent manner with enhanced IgA secretion. In conjunction with the data ob-
tained with density-separatedcells presented above, these results are consistent with
a model in which IL-6 acts on activated mIgA+ (IgA-committed) B cells to support
their synthesis of increased amounts of IgA.
mrIL-6 Supports an Increase in theNumber ofIgA-secretingCells in theAbsenceofProliferation.
Based on the comparative "background" levels ofIgA synthesis in nonsupplemented
cultures oflow density versus high density and mIgA' versus mIgA- PP B cells,
it is clear that the PP B cell population represents an enriched source ofactivated
mIgA' cells that are either secreting IgA at the time of isolation, or that will pro-
gressto IgA secretion intheabsence ofexogenously added lymphokines. The abilityPPS colts
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of IL-6 to increase the absolute amount of secreted IgA could be mediated through
proliferation and expansion of these "synthesis committed" cells, by enhancement
ofthe syntheticrate of thesecommittedcells, or throughthe recruitment anddifferen-
tiation to IgA secretion of additional cells from the activated mIgA+ pool. To
differentiate between these possibilities, we measured the number of IgA secreting
cells andthe amount ofIgA secreted as afunction oftime. As detected in an ELISPOT
assay, the number of cells secreting IgA in the presence of exogenously added IL-6
rose to near aplateau number (greater than eight timesbackground) within the first
24 h of culture (Table I). Additionally, no difference in the number of viable cells
was detected over the first 3 d of culture, either in the presence or absence of IL-6.
Parallel studies demonstrated that in the presence of IL-6 plateau levels of IgA were
secreted into the culture supernatants by day 3 (data not shown). These data dem-
onstrate that the IL-6 enhancement of IgA synthesis measured in these studies is
a rapid event and do not indicate that proliferation is involved. Rather, the results
suggest that the PP contain a significant fraction of IL-6-sensitive activated m1gA'
B cells that are poised to terminally differentiate to IgA secretion in the presence
of this regulatory lymphokine.
TABLE I
IL-6 Enhances the Frequency of IgA-producing Cells in PP B Cell Cultures
FIGURE 6.
￿
mrIL-6 effects on FACS separated
PP Bcell populations. PP Bcells obtained by
panningwere stained with FITC-labeled anti-
a and separated into mIgA' and mIgA-
populations. Whole PP B cells and mlgA-
PP B cells were cultured at 105 cells/culture
for 7 dwith IL-6. mIgA' PP B cells were cul-
tured at 5 x 104 cells/culture for 7 d with IL-
6. IgM(EM), IgG(p), andIgA(/)levels in
culture supernatants were determined by iso-
type-specific RIA. Values represent the mean
± SD of triplicate cultures.
Panning purified PP B Cells (106 cells/culture) were incubated for 1 or 3 dwith
mrIL-6 at a final concentration of 50 U/ml. Control cultures were incubated
in culture medium alone. At the end of culture, cell viability was determined
by trypan blue dye exclusion and IgA spot-forming cells (SFC) responses were
examined by ELISPOT assay (see Materials and Methods).
Exp.
Day
mrIL-6
Number of IgA
1
None
SFC/105 B Cells
Day
mrIL-6
3
None
1
2
3
9,440 t 640
ND
11,920 t 720
1 .160 t 120
ND
1,400 t 80
9,760
6,560
16,001
t 800
t 660
f 640
740 t 120
280 t 34
1,180 t 1202142
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Discussion
The PP are major IgA inductive sites in higher mammals (26); however, we only
partially understand the mechanisms involved in regulation of this response. Past
studies have shown that isolated T cells from PP can selectively regulate IgA syn-
thesis in vitro (49). Other studies using cloned Tcells from this tissue have shown
that two broad regulatory mechanisms are operative (50-53). First, cloned T cells
from mice (50) and hybridoma cell lines from human appendix (51) could appar-
ently induce B cells to switch from mIgM to mIgA expression. Second, more clas-
sical Th cell clones were also derived from PP that preferentially supported IgA re-
sponses (52, 53). Taken together, these studies would suggest that PP T cell subsets
occurthat can produce switch factors, while possibly others may produce cytokines
for regulation ofIgA synthesis. In this latter respect, it islikely that a unique profile
of cytokines will be of importance in the IgA response.
We have taken advantage of two major aspects of IgA inductive sites, e.g., the
presence of endogenously triggered B cells that are in cell cycle and an increased
frequency of B cells which have committed to IgA. This has allowed us to avoid
the useofpolyclonal B cell activators such as LPS and PWM, which can also induce
certain isotype response patterns and thus possibly skew results and their interpre-
tations. Ourpast studies and thoseofothers have shownthat mrIL-5-enhanced IgA
synthesis in PPB cellcultures (36, 54, 55). Theuse ofLPS inthesePP B cellcultures
yielded somewhat discrepant results. In one study, it was shown that rIL-5 induced
IgA synthesis in LPS-triggered mIgA` but not mIgA- B cells (54). However, the
second study suggested that IL-5 enhanced IgA synthesis in LPS-stimulated, mIgA-
PP B cells (55). We addressed the effects of mrIL-5 by addition to nonstimulated
cultures, and showed thatthis interleukin significantly enhanced IgA synthesis (36).
Thus, the PP B cell system offers the advantage ofprovision ofB cells that are cy-
cling and that express receptors for cytokines that regulate the events that lead to
production of this isotype.
We have examined in this study all ofthe currently available interleukins (except
IL-3), as well as murine IFN-y, TNFa, and TGF-(3 forpotential effects on murine
PP B cells. Our results clearlyshowthat rIL-5 and, especially, rIL-6 induce significant
increases in IgA synthesis. This does not prove that the other cytokines do not con-
tribute to B cell activation or proliferative responses; however, it does suggest that
these othercytokines alone arenotinvolved interminal events thatlead totheproduc-
tion ofIgA. It would also suggest that the effect seen with rIL-6 was not due to con-
tamination with one oftheothercytokines tested. Since the effect ofIL-6 (including
both human and mouse rIL-6) is so pronounced for enhancement ofIgA synthesis
in PP B cell cultures, we have extensively studied this effect..
It has been shown that resting B cells do not express IL-6R (15), and others have
shownthat human tonsillarB cells, whichwere refractory to IL-6, could be induced
to respondafter stimulation with PWM (56). Our studies were directed towardsde-
termining whether activated B cells would also be responsive to IL-6. Thus, PP B
cells were separatedonPercoll gradients into activated (blast, lowdensity) and resting
(small, high density) B cell populations. Generally, IL-6 induced two- to threefold
higher IgA responses in thelow density B cell population than occurred in the high
density population; however, IL-6 did induce small B cells to respond and to ulti-
mately secrete IgA in vitro. Separation ofB cells on densitygradients does notresultBEAGLEY ET AL.
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in complete separation ofactivated and resting B cells. The receptor on human B
cells has been fully characterized (15) and cloned (16); however, little is known re-
gardingthe IL-6R on murine B cells. We are therefore performing studies to iden-
tify IL-6R on murine PP B cell subpopulations.
It isclearly possible that IL-6could induce PPB cells toundergo an isotypeswitch
to IgA and this possibility has been extensively investigated. First, we have previ-
ously shown that both high and low density PP B cell populations contain approxi-
mately equal numbers ofmIgA' B cells (36). Thus, experiments were undertaken
with PP B cells that were depleted of mIgA+ B cells by flow cytometry. When
mIgA- B cells were cultured with mrIL-6, no increase in IgA secretion was ob-
served. However, when cultures containing enriched numbers ofmIgA' PP B cells
were examined, optimal levels of mrIL-6 induced up to 13 14g/ml of IgA in B cell
cultures containing -5 x 104 mIgA+ B cells. In other studies, we have shown that
depletion of mIgA+ B cells from both low and high density B cell cultures abrogated
the IL-6 effect. Taken together, these results indicate that the major target of IL-6
in the PP B cell population is a cell that has already committed to IgA.
Since mrIL-6 induced some IgA synthesis in small B lymphocyte populations,
it was importantto determine ifthis interleukinwas inducing both proliferativeand
differentiative signals. Ofcourse, most studieshaveindicatedthat IL-6actson dividing
B cells that express IL-6R and promotes terminal differentiation to Ig secretion (1).
Our studies support this mode of IL-6 effect . When PP B cell cultures were sup-
plemented with mrIL-6, it was shown that between 24 and 72 h of incubation, the
cells did not undergo significant rounds ofdivision. No increase in [3H]thymidine
incorporation was detected in IL-6-supplemented cultures compared with control
cultures at 24, 48, or 72 h(datanot shown). However, the numbers ofB cells secreting
IgA dramatically increased in cultures assessed at 1 and 3 d in that there was an
N8-fold increase on day 1 and a 15-18-fold increase by day 3 ofculture. Theseresults
clearly indicate that mrIL-6 induces PP B cells to terminally differentiate into IgA-
producing cells. It would also appear that most IL-6-responsive cells express mIgA
and these cells are subsequently stimulated to produce IgA.
We were aware ofthepossibilitythat the mrIL-6 preparation could contain asmall
amount ofanother cytokine, which would account for the observed effect. One pos-
sibility would be TGF-0, which is known to be produced by COS-7 cells and has
asimilarmolecularmass to IL-6 (25 kDforTGFa and 26 kD forIL-6). We directly
addressed this point by testing several relevant concentrations of TGF0 (8 pg to
1 ng) in PP B cell cultures. We were unable to observe any changes in levels ofIgA
(IgM or IgG) secreted. More direct evidence for an IL-6 effect was provided by
studieswith hrIL-6 and anti-IL-6. In this case, weobtained anidenticaldose-dependent
increase in IgA synthesis with human IL-6 and this effect was blocked specifically
bytheanti-IL-6 antibody. Wethus conclude that the dramatic effects ofboth mouse
andhuman IL-6 on murine IgA synthesis are directlydue to these interleukins and
not to contaminating proteins.
The results presented thus far suggest that IL-6 plays an important role in the
terminal stages ofmucosalimmune responses. Wehave preliminarydata suggesting
that Tcells from murine PP secrete IL-6 and these studies are ongoing. Further-
more, IL-6 is knownto be produced by a wide variety ofcells includingT cells (57),
macrophages (58, 59), andfibroblasts(3). Others haverecentlyshown thatIL-6mRNA2144 rIL-6 ENHANCES IgA SYNTHESIS BY PEYER'S PATCH B CELLS
is transcribed at high levels in human spleen, liver, kidney, and peripheral blood
leukocytes (60). Receptors for IL-6 have also been found on resting T cells (16), and
IL-6 has been shownto affect the development ofhemopoietic stem cells and thymo-
cytes. These studies indicate that this lymphokine plays an important role in the
development of many cell types, including B cells. Because of the pleiotropic nature
of IL-6 and its widespread production by different tissues, it is likely that events
that drivePP B cells toward the IgA isotype occur before these cellsbecome respon-
sive to IL-6, and that the major function of IL-6 in the PP is to induce the terminal
differentiation of these cells into IgA-secreting plasma cells.
Summary
Freshly isolated murine PP B cells were cultured with 10 different cytokines, in-
cluding IL-la, IL-2, IL-4, IL-5, IL-6, IL-7, IFN--y, TNFa, and TGF/3, to inves-
tigate a possible role for these cytokines in induction of Ig synthesis. Of interest was
the finding that only IL-5 and both mouse recombinant (mr) and human recom-
binant (hr) IL-6 enhanced IgA synthesis. The effect was greater with either mrIL-6
or hrIL-6 than with mrIL-5. IL-6 induced cycling mIgA+ PP B cells to secrete high
levels of IgA (-7-fold increase over control). Of importance was the finding that
mrIL-6 had little effect on secretion of IgM or IgG by PP B cell cultures. hrIL-6
also increased IgA secretion by PP B cells and this enhancement was abolished by
a goat anti-hrIL-6 antiserum. mrIL-6 did not cause B cell proliferation but induced
a sharp increase in numbers of B cells secreting IgA. Isotype-switching was not a
mechanism for this marked increase in IgA synthesis since mIgA- PP B cells were
not induced to secrete IgA by mrIL-6. From these studies we conclude that IL-6
plays an important role in promoting the terminal differentiation of PP B cells to
IgA-secreting plasma cells.
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